帕潘立酮棕榈酸酯
医学
抗精神病药
医疗补助
精神分裂症(面向对象编程)
帕利哌酮
利培酮
精神科
内科学
医疗保健
经济增长
经济
作者
Kruti Joshi,Marie-Hélène Lafeuille,Rhiannon Kamstra,Sean Tiggelaar,Patrick Lefebvre,Edward S. Kim,Yong Yue,Neeta Tandon
标识
DOI:10.2217/cer-2017-0043
摘要
Aim: Compare medication utilization, costs and healthcare resource use in schizophrenia patients with substance-related disorders initiated on once-monthly paliperidone palmitate (PP1M) or an oral atypical antipsychotic (OAA). Materials & methods: Data from six Medicaid states (07/2009–03/2015) were used to compare outcomes between PP1M and OAA patients. Results: PP1M patients had higher 12-month antipsychotic adherence and persistence than OAA patients. PP1M patients had lower medical (mean monthly cost difference [MMCD] = US$-191, p = 0.020), higher pharmacy (MMCD = US$250, p < 0.001) and similar total costs (MMCD = US$59, p = 0.517) during the overall follow-up. PP1M patients had lower rates of outpatient visits and inpatient days but higher rates of mental health-related utilization. Conclusion: PP1M was associated with higher antipsychotic adherence and persistence, and similar total costs versus OAA.
科研通智能强力驱动
Strongly Powered by AbleSci AI